University of Eastern Finland
The Tanila group works on the neurobiological underpinnings of memory impairment both due to subtle age-related changes and as a consequence of beta-amyloid accumulation, as well as on diet and drug based therapies for AD in transgenic mouse models. This is of course the ideal combination one looks for in a project like this.
The Soininen group has a long-term experience and she has conducted several large projects in molecular epidemiology, genetics, diagnostics and therapy of Alzheimer's disease, as well as neuroimaging in aging and dementia. She has been running large scale population based studies in life style and genetic risk factors of Alzheimer’s disease and mild cognitive impairment. Her list of publication includes 450 papers and over 350 original publications. She has been P.I. in 20 Clinical Drug Trials in the last 10 years. She will be heading the clinical trial project. Among her staff a Miia Kivipelto, MD, PhD, and docent in neuroepidemiology, who is maybe the most promising young expert on epidemiology of Alzheimer's disease for the topics of our research and already an authority on that topic (over 100 publications). Kivipelto has positions in Finland and Sweden and will together with Gustafson head the epidemiological studies.